Heart Transplant vs. Heart Pump – Debate Comes to Life

HeartWare HVAD Heart Pump

HeartWare HVAD Heart Pump

Decades of failed attempts to solve the organ rejection problem and the fast-improving technology surrounding left ventrical assist devices (LVAD) or heart pumps have combined to create a medical debate arount the pump or transplant decision.  Companies such as Thoratec (Nasdaq:THOR), HeartWare (ASX:HIM – expected to list on Nasdaq in January) and Abiomed (Nasdaq:ABMD) are leading the way with newer, smaller and more durable heart pumps that are designed to not only keep patients alive while they await a donor heart, but to also sustain life and quality-of-life for many years as a permanent treatment.

The following article from the London Times does a good job of outlining the transplant vs. pump discussion: http://www.timesonline.co.uk/tol/news/uk/health/article5039521.ece


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s